CN102210841B - Chinese medicinal preparation for treating central serous retinopathy - Google Patents

Chinese medicinal preparation for treating central serous retinopathy Download PDF

Info

Publication number
CN102210841B
CN102210841B CN2011101428677A CN201110142867A CN102210841B CN 102210841 B CN102210841 B CN 102210841B CN 2011101428677 A CN2011101428677 A CN 2011101428677A CN 201110142867 A CN201110142867 A CN 201110142867A CN 102210841 B CN102210841 B CN 102210841B
Authority
CN
China
Prior art keywords
radix
medicinal preparation
chinese
chinese medicinal
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2011101428677A
Other languages
Chinese (zh)
Other versions
CN102210841A (en
Inventor
刘永华
房永红
费文轩
张丽翠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2011101428677A priority Critical patent/CN102210841B/en
Publication of CN102210841A publication Critical patent/CN102210841A/en
Application granted granted Critical
Publication of CN102210841B publication Critical patent/CN102210841B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a Chinese medicinal preparation for treating central serous retinopathy. The Chinese medicine is characterized by being prepared from the following Chinese medicines by weight: 10 to 15g of bupleurum, 15 to 20g of Chinese angelica, 10 to 15g of white paeony root, 15 to 20g of Indian buead, 15 to 20g of rhizome atractylodis macrocephalae, 15 to 20g of pilose asiabell root, 25 to 30g of prepared rehmannia root, 10 to 15g of achyranthes bidentata, 10 to 15g of medlar, 12 to 18g of south dodder seed, 20 to 30g of glossy privet fruit, 10 to 15g of zedoary, 10 to 15g of cinnamomvine, 8 to 15g of alisma plantagoaquatica and 6 to 10g of liquoric root. A preparation method of the Chinese medicinal preparation comprises the following steps of: soaking the Chinese medicines, adding 1,200 to 1,500kg of water, heating, boiling, decocting over slow fire for 40 to 60 minutes, removing dregs and filtering to obtain decoction. One dose of Chinese medicinal preparation is taken every day, and 10 days constitute a course. The Chinese medicinal preparation has the good effect of treating the central serous retinopathy, has no toxic or side effects, is high in cure rate and convenient to take, and belongs to a Chinese medicinal preparation.

Description

The Chinese medicine preparation that therapeutic community's property serous chorioretinopathy becomes
Technical field
The present invention relates to technical field of Chinese medicines, the Chinese medicine preparation that therapeutic community's property serous chorioretinopathy that particularly a kind of pure Chinese medicine is made becomes.
Background technology
Slurry during central serous chorioretinopathy is called for short is a kind of be common in young and middle-aged, distribute and oculopathy that have certain self limiting.Primary disease is sent out in healthy male well, and the women is less, and men and women's morbidity ratio is roughly 8~9: 1, can be simple eye or the eyes morbidity, and age of onset is mostly between 25~50 years old.Though primary disease has certain self limiting, be prone to recurrence, long-term recurrence will cause macula retinae district cicatrization, thereby cause the irreversible damage of visual function.The primary disease pathogenesis is not very clear and definite; Think mostly because certain factor causes the infringement of PE barrier function; Thereby the CC net spills a large amount of proteinaceous liquid, infiltrates under the neuroepithelium through PE infringement place, causes the disciform detachment of neural sensation layer.Slurry mainly is that dependence vitamin and short metabolic drug are oral in the western medical treatment, and takes laser and PDT treatment according to the seepage situation, all can not obtain satisfactory effect.Chinese medicine thinks that central serous chorioretinopathy belongs to " chromatopsia " category; Say that like " Standards of Diagnosis and Treatment miscellaneous diseases seven apertures door " " chromatopsia card; non-if the choice refreshments of firefly star, cloud and mist two cards is also rectangular is that all things of looking of order have sheet very then current in it is not demonstrate,proved to control it because of its color.If see green grass or young crops, green, blue, green color, be the disease of deficiency of the liver and kindey, by deficiency of YIN insufficiency of blood, the seminal fluid attenuation, bile is not enough, and gas is weak and loose ... as if seeing Huang Chizhe, be that fiery native network has wound ... ".It is thus clear that primary disease is many because of both liver and kidney deficiency, due to the loss of nutrient of eyes, or dysfunction of the spleen in transportation, the general order of phlegm-damp; That should blame is dirty in liver spleen kidney three, and successive dynasties document treatment primary disease is many to be main with liver and kidney tonifying, invigorating spleen to remove dampness.But ignored feelings will is the key factor in the primary disease morbidity.Because showing the predisposing factor of its morbidity, Recent study has following several kinds: 1. psychological factor.Research infers that psychological factor is one of origin cause of formation of middle slurry, and melancholia and hysteria scale score are apparently higher than normal level among the middle slurry patient.2. middle slurry patient premorbid often has stress situation, and common inducement is not had enough sleep, anxiety, anxious state of mind etc.So treatment primary disease simple liver and kidney tonifying, invigorating spleen to remove dampness curative effect are not ideal enough.The present invention then sets about from feelings will, proposes stagnation of liver-QI and violates spleen, and dysfunction of the spleen in transportation, the general order of phlegm-damp are the important pathogenesis of primary disease, and is principle of treatment with dispersing the stagnated live-QI to relieve the stagnation of QI reason spleen, is aided with invigorating spleen to remove dampness, tonifying kidney for improving eyesight medicine, obtains satisfactory effect clinically.
Summary of the invention
The Chinese medicine preparation that the object of the present invention is to provide a kind of therapeutic community's property serous chorioretinopathy to become.Chinese medicine preparation of the present invention has the effect of dispersing the stagnated live-QI to relieve the stagnation of QI, invigorating spleen to remove dampness, tonifying kidney for improving eyesight.
Technical scheme of the present invention is:
The Chinese medicine preparation that therapeutic community's property serous chorioretinopathy becomes is characterized in that it being that Chinese medicine by following weight is made: Radix Bupleuri 10~15g, Radix Angelicae Sinensis 15~20g, the Radix Paeoniae Alba 10~15g; Poria 15~20g, the Rhizoma Atractylodis Macrocephalae 15~20g, Radix Codonopsis 15~20g, Radix Rehmanniae Preparata 25~30g; Radix Achyranthis Bidentatae 10~15g, Fructus Lycii 10~15g, Semen Cuscutae 12~18g, Fructus Ligustri Lucidi 20~30g; Radix Curcumae 10~15g, Rhizoma Dioscoreae 10~15g, Rhizoma Alismatis 8~15g, Radix Glycyrrhizae 6~10g.
Manufacture method: get above-mentioned weight Chinese medicine, after concocting, add water 1200-1500kg, after the heated and boiled slow fire boiling 40-60 minute, drag for slag and be filtered into decoction, every day potion, 10 days courses of treatment.
The pharmacological effect of each crude drug is in the prescription:
Radix Bupleuri: bitter in the mouth, flat, return liver, gallbladder meridian.Function: deliver, bring down a fever, soothing the liver, resolving depression, yang invigorating.Compendium of Material Medica: " control yang-energy and sink, suppressing the hyperactive liver, gallbladder, three warmers, envelope be fire mutually, and headache, dizzy, and blurred vision, swelling pain are hidden from view.”
The Rhizoma Atractylodis Macrocephalae: bitter in the mouth, sweet, warm in nature, return spleen, stomach warp.Invigorating the spleen and benefiting QI, the dampness diuretic, the activating the spleen removing dampness is with exhausted phlegm-damp.Be used to treat insufficiency of the spleen phlegm-damp, " medicine origin " record: " the dry and middle QI invigorating of dehumidifying benefit.”
Radix Angelicae Sinensis: sweet, hot, temperature.Return liver, the heart, spleen channel.Tonifying blood and regulating menstruation is invigorated blood circulation.The disease of treatment blood deficiency and blood stasis.And the hot row temperature of these article is logical, is the key medicine of blood-activating and qi-promoting.
Poria: sweet in the mouth, light, property is flat, GUIXIN, lung, spleen, kidney channel.Promoting diuresis to eliminate damp pathogen, invigorating the spleen for dissipating phlegm.Be used to treat edema phlegm retention, cardiopalmus, insomnia." generation mend vegetarian medical book ": " Poria simply, for controlling the expectorant principal agent, expectorant this, water also, Poria can be gone water.Expectorant is moving, wets also, and Poria is feasible again wet.”
The Radix Paeoniae Alba: bitter, sour, be slightly cold.Return liver, spleen channel.The yin fluid astringing that nourishes blood, easing the affected liver to relieve pain, suppressing liver-YANG.Cure mainly the breast side of body epigastric pain of incoordination between the liver and spleen.Shennong's Herbal: " main pathogen stomachache, pain relieving, diuresis, QI invigorating.”
Radix Codonopsis: sweet, flat.Return spleen, lung meridian.The spleen reinforcing lung qi is enriched blood, and promotes the production of body fluid.Cure mainly syndrome of qi deficiency of spleen and lung." Bencao Congxin ": " invigorating the spleen and replenishing QI, and taste, relieving thirst and restlessness.Middle feeble QI is empty, mends in order to transfer, very safety.”
Above Six-element medicine, wherein Radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Poria, the Radix Paeoniae Alba are the key component of XIAOYAO POWDER, XIAOYAO POWDER is the name side of traditional Chinese medical science regulating the liver and spleen.With the Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI, the irritability bar is reached in the side.The Radix Paeoniae Alba is bitter to be slightly cold, the yin fluid astringing that nourishes blood, easing the affected liver emergency; The sweet arduous temperature of Radix Angelicae Sinensis nourishes blood and blood, and can regulate the flow of vital energy, and is the gas medicine in the blood; Return, Chinese herbaceous peony is identical with Radix Bupleuri, tonifying liver body and help liver usefulness, make blood and then liver fill with, blood that then liver is gentle.Wood Yu Ze soil declines, and hepatopathy is easy to transmitting into the spleen, so with the Rhizoma Atractylodis Macrocephalae, Poria invigorating the spleen and benefiting QI, not only real soil is wooden to press down, and make nutrient blood biochemistry active.In addition Radix Codonopsis invigorating the spleen and benefiting QI again, the merit of long memorial liver resolving depression invigorating spleen to remove dampness altogether.。
Radix Rehmanniae Preparata: sweet in the mouth, slightly warm in nature is returned liver, kidney channel.Function nourishing the blood and yin, vital essence replenishing and marrow benifiting are the key medicine of tonifying kidney-yin.Compendium of Material Medica: " fill out bone marrow, longue meat, promoting generation of vital essence and blood, the tonifying five ZANG-organs internal injury is not enough, promoting blood circulation, sharp knowledge.”
Radix Achyranthis Bidentatae: bitter, sweet, sour, flat.Return liver, kidney channel.Promoting blood circulation to restore menstrual flow, invigorating the liver and kidney, relieving stranguria by diuresis.Treatment soreness of waist and knee joint edema, all diseases of dysuria.
Rhizoma Dioscoreae: sweet, flat.Return spleen, lung, kidney channel.Spleen reinforcing is promoted the production of body fluid, the lung benefiting the kidney invigorating.Cure mainly syndrome of spleen-deficiency, nephrasthenia syndrome, deficiency of the lung card.Compendium of Material Medica: " kidney tonifying gas, strengthening the spleen and stomach.”
Rhizoma Alismatis: sweet, cold.Return kidney, urinary bladder channel.Inducing diuresis to remove edema, eliminating dampness by diuresis.The treatment edema, dysuria, disease such as have loose bowels.Compendium of Material Medica: " preventing or arresting vomiting is told for eliminating dampness by diuresis heat, row phlegm retention, dysentery, colic, beriberi.”
Above-mentioned four flavors are the main medicine in the LIUWEI DIHUANG WAN, the merit of playing the kidney invigorating and essence nourishing altogether.
Radix Curcumae: hot, bitter, cold.Return liver, gallbladder, heart channel.Promoting blood circulation and stopping pain, promoting QI circulation for relieving depression.The breast flank pain of treatment qi depression to blood stasis.Essentials of Matea Medica: " circulation of qi promoting, resolving depression, removing blood stasis with potent drugs, the stagnation of liver-QI of loosing.”
Fructus Lycii: sweet, flat.Return liver, kidney channel.Nourishing the liver and kidney, replenishing vital essence to improve eyesight.The visual deterioration of treatment due to the asthenia of essence and blood, cataract blurred vision, dizzy disease such as dizzy.Outstanding two dryness and uneasy feeling of the eye that are used for the hepatic and renal YIN deficiency more, the cataract blurred vision, like QIJU DIHUANG WAN, " Bencao Jingshu ": " be the Liver and kidney kidney-YIN being deficient, the key medicine of tired interior-heat tonification is so be article on the replenishing vital essence to improve eyesight.”
Semen Cuscutae: hot, sweet, flat.Return the kidney,liver,spleen warp.The kidney invigorating and essence nourishing, nourishing the liver to improve visual acuity.Cure mainly deficiency of the liver and kindey, poor vision.These article nourishing the liver and kidney benefit intensive culture blood and making eye bright, normal, Semen Plantaginis same usefulness yellow with Radix Rehmanniae Preparata, like ball in the scape, Shennong's Herbal: " of a specified duration obey make eye bright, make light of one's life by commiting suicide and prolong life.”
Fructus Ligustri Lucidi: sweet, bitter, cold.Return liver, kidney channel.Nourishing the liver and kidney, crow must make eye bright.Be applicable to cards such as poor vision due to the hepatic and renal YIN deficiency, visual deterioration, early whitening of beard and hair.Compendium of Material Medica: " reinforcing YIN-essence, strong waist knee joint bleach and send out, and make eye bright.”
Radix Glycyrrhizae: sweet in the mouth, property is flat, returns spleen channel.Invigorating the spleen and replenishing QI, the mediation property of medicine.
Treatment mechanism of the present invention:
Radix Bupleuri has extensively central inhibitory action such as calmness, stable, analgesia, and can increase the protein biosynthesis and promote tissue repair.Rhizoma Atractylodis Macrocephalae diuresis, anticoagulant, enhancing human body immunity function, its volatile oil has sedation.Radix Angelicae Sinensis has blood vessel dilating, anticoagulant, antioxidation and the effect of removing free radical, and histanoxia is had the obvious suppression effect, thereby promotes tissue repair; The Radix Paeoniae Alba can make the cellular immune function that is in low state recover normal, and the acute inflammation edema is had inhibitory action.Poria has diuresis, abirritative effect.Its effective ingredient pachyman has regulating action to body's immunity.
Radix Rehmanniae Preparata has obvious inhibitory action to the central nervous system, and has the adjusting immunologic function.The Radix Codonopsis improving immunocompetence; Also have slow down aging, antioxidation, improvement to organize oxygen supply, promote the tissue repair effect.Radix Achyranthis Bidentatae has antiinflammatory, analgesic activity, can the human body immunity improving function.Rhizoma Dioscoreae has stronger facilitation to mouse cell immunologic function and humoral immunization, and effects such as antioxidation are arranged.
The effect that Radix Curcumae has calmness, improves immunologic function, removes free radical, anti-inflammatory analgesic.Rhizoma Alismatis has diuresis, immunoregulation effect; But Fructus Ligustri Lucidi enhancing non-specific immunity function has dual regulation to unusual immunologic function; And can effectively remove free radical; Semen Cuscutae is irritated stomach has therapeutical effect to rat galactose-cataract, and it can obviously improve organizes oxygen supply.Fructus Lycii has promotion and regulating action to immunity; And can effectively remove free radical, promotion tissue repair.Radix Glycyrrhizae has the effect of parahormone appearance, can regulate the immune function of body.
Pharmacology's mechanism that analysis-by-synthesis therapeutic community's property serous chorioretinopathy of the present invention becomes possibly be that blood vessel dilating, microcirculation improvement, removing free radical, antiinflammatory, the immune function of adjusting body, swelling diuretic, calmness, improvement organize oxygen supply, promote aspect such as tissue repair.
The present invention's advantage of filling a prescription:
1. the present invention's therapeutic community's property serous chorioretinopathy of filling a prescription becomes good effect, and cure rate is high, and clinical total effective rate is 96.7%.
2. can effectively promote the optical fundus seepage to absorb, eliminate the macular area edema, obviously improve the PE layer function, reduce the macula lutea cicatrization, thereby improve vision, alleviate and look thing variable color and distortion symptom.
3. pure Chinese medicinal preparation, taking convenience has no side effect.
The specific embodiment
Below in conjunction with embodiment the present invention is elaborated.
Embodiment 1: Radix Bupleuri 15g, Radix Angelicae Sinensis 20g, Radix Paeoniae Alba 15g, Poria 20g, Rhizoma Atractylodis Macrocephalae 20g, Radix Codonopsis 20g, Radix Rehmanniae Preparata 30g, Radix Achyranthis Bidentatae 15g, Fructus Lycii 15g, Semen Cuscutae 18g, Fructus Ligustri Lucidi 30g, Radix Curcumae 15g, Rhizoma Dioscoreae 15g, Rhizoma Alismatis 15g, Radix Glycyrrhizae 10g.Get above-mentioned weight Chinese medicine, after concocting, add water 1500kg, slow fire boiling is 60 minutes after the heated and boiled, drag for slag and be filtered into decoction, every day potion, 10 days courses of treatment.
Embodiment 2: get Radix Bupleuri 10g, Radix Angelicae Sinensis 15g, Radix Paeoniae Alba 10g, Poria 15g, Rhizoma Atractylodis Macrocephalae 15g, Radix Codonopsis 15g, Radix Rehmanniae Preparata 25g, Radix Achyranthis Bidentatae 10g, Fructus Lycii 10g, Semen Cuscutae 12g, Fructus Ligustri Lucidi 20g, Radix Curcumae 10g, Rhizoma Dioscoreae 10g, Rhizoma Alismatis 8g, Radix Glycyrrhizae 6g.Get above-mentioned weight Chinese medicine, after concocting, add water 1200kg, slow fire boiling is 40 minutes after the heated and boiled, drag for slag and be filtered into decoction, every day potion, 10 days courses of treatment.
Clinical trial data:
For verifying therapeutic effect of the present invention, the patient of the central serous chorioretinopathy of my institute's treatment over 2007~2010 years has been carried out clinical trial:
1, data and method
1.1 diagnostic criteria
1.1.1 Western medicine diagnose standard
Confirm diagnostic criteria with reference to Hui Yannian chief editor " ophthalmology ": 1. be more common in young and middle-aged male, outbreak repeatedly has the spontaneous recovery tendency.2. central amblyopia has metamorphopsia, variable color.3. optical fundus: the macular area edema, color is dark red, rounded or elliptic bulge, the central fovea luminous reflectance disappears.4. fluoroscopic visualization inspection: the venous phase utmost point portion of can seeing after has one or more fluorescence points to occur, and is spurting or ink marks shape gradually, expands as the hyperfluorescence speckle.
1.1.2 tcm diagnosis standard
Diagnostic criteria with reference to Ceng Qinghua chief editor " ophthalmology of Chinese medicine " chromatopsia: 1. sallow shadow at the moment, look thing variable color, distortion; 2. visual deterioration.But often be not less than 0.2; 3. rounded reflective wheel of optical fundus macula lutea portion retinal edema, the reflective disappearance of central fovea has the yellow-white point-like to ooze out; 4. inspection such as fluorescence fundus angiography helps diagnosis.
1.1.3 the standard of including in: (1) meets above-mentioned tcm diagnosis standard; (2) meet above-mentioned Western medicine diagnose standard; (3) sign Informed Consent Form by me or family members; (4) meet following case exclusion standard simultaneously.
1.1.4 case exclusion standard: ocular disease and medical histories such as glaucoma, uveitis, ocular injury are got rid of in (1); (2) gestation or women breast-feeding their children, to this medicine allergy sufferers; (3) non-diabetic, hypertension and other systemic disease medical history, (4) all standards of including in that do not meet, by the regulation medication, can't judge curative effect or data not congruent affect the treatment with safety judgement person.
1.2 physical data
60 routine central serous chorioretinopathy patients are divided into treatment by Chinese herbs group (hereinafter to be referred as the treatment group) 30 examples, wherein male 26 examples, women 4 examples at random; 23~41 years old age, average 29.3 years old; The course of disease is the shortest 5 days, and is the longest 3 years, average 10.3 months.Western medicine group (hereinafter to be referred as matched group) 30 examples, wherein male 27 examples, women 3 examples; 26~39 years old age, average 30.2 years old; The course of disease is the shortest 7 days, and is the longest 4 years, average 12.9 months.Two groups age, sex, the course of disease be there was no significant difference (P>0.05) relatively, has comparability.
Method: 30 examples are organized in (1) treatment, give this medicine.Decocting is condensed into the 400ml/ agent, sooner or later respectively obeys 200ml 1 dose of every day, and taking 15 days continuously is 1 course of treatment, judges curative effect.(2) matched group 30 examples adopt the doctor trained in Western medicine supporting treatment to give each VITAMIN C TABLET, 0.2g, every day three times, compound vitamin B, 2, every day three times.15 days is a course of treatment, judges curative effect.
1.3 observation item
1.3.1 safety observation project:
(1) general test item: heart rate, blood pressure, breathing, pulse;
(2) routine blood test, routine urinalysis, stool routine examination;
(3) electrocardiogram, liver function (ALT), renal function (BUN, Cr).
1.3.2 health giving quality observation item:
(1) vision;
(2) look thing variable color, metamorphopsia degree;
(3) fluorescence fundus angiography (FFA) cross-reference as a result;
(4) optical fundus optical coherence scanning (OCT) cross-reference;
1.3.3 main curative effect index observational technique:
(1) vision and look the thing variable color, distortion is observed: before the treatment and treatment beginning back observed and recorded every day 1 time.
(2) FFA result: behind the abundant mydriasis of 0.5% Tropicamide and Phenylephrine eye drop, adopt Heidelberg, Germany confocal laser optical fundus scanning system to check.
(3) OCT inspection: the STRATUS OCT (OCT-3000 type) that uses Carl Zeiss company to produce carries out macular area scanning: be the center with central fovea of macula, the linear scanning that radial 6mm is long.Scan depths 2mm adopts admittedly interior apparent place (suffering from green bright spot in the eye fixation camera lens) checked.Inspection is preceding with the abundant mydriasis of 0.5% Tropicamide and Phenylephrine eye drop.
More than each pointer operation and observe and to arrange respectively to accomplish by same people.
1.4 efficacy assessment standard:
1.4.1 criterion of therapeutical effect
" traditional Chinese medical science disease diagnosis criterion of therapeutical effect ", Hui Yannian chief editor " ophthalmology " and Duan Junguo chief editor " Chinese and western medicine ophthalmology " with reference to State Administration of Traditional Chinese Medicine's nineteen ninety-five issue formulate.
1. cure: vision bring up to 1.0 or more than, optical fundus macula lutea portion edema disappears and oozes out absorption, looks thing variable color and metamorphopsia and disappears basically;
2. take a turn for the better: vision improves more than 1 row, and optical fundus macula lutea portion edema alleviates oozes out minimizing, looks thing variable color and metamorphopsia and alleviates;
3. invalid: clinical symptoms and sign there are not significant change.
1.4.2 statistical procedures
Measurement data is used
Figure BSA00000506838300071
Expression, enumeration data adopts X 2The t check is adopted in check, measurement data.All data are handled by 11.5 editions statistical softwares of SPSS.There is statistical significance P<0.05.
2 therapeutic outcomes
2.1 clinical efficacy comprehensively relatively reaches analysis (seeing table 1)
Table 1 clinical efficacy comprehensively compares n (%)
Group n cures the invalid effective percentage that takes a turn for the better
Treatment organizes 30 21 (70.0%) 8 (26.7%) 1 (3.3%) 96.7%
Matched group 30 10 (33.3%) 12 (40.0%) 8 (26.7%) 73.3%
The cure rate of treatment group and matched group and total effective rate more all have significant difference (P<0.05), show that treatment group curative effect is superior to matched group.
2.2FFA inspection cross-reference (seeing table 2):
Table 2FFA check result is n (%) relatively
It is invalid that group n seepage disappearance seepage reduces
Treatment organizes 30 16 (53.0%) 13 (43.3%) 1 (3.3%)
Matched group 30 10 (33.3%) 12 (40.0%) 8 (26.7%)
Treatment group and matched group relatively have utmost point significant difference (P<0.01) through FFA inspection, show the treatment group reduce that the optical fundus is oozed out, curative effect obviously is superior to matched group aspect the edema.
2.3OCT inspection cross-reference (seeing table 3)
Table 3OCT check result is n (%) relatively
Group n net take off the disappearance net take off alleviate invalid
Treatment organizes 30 16 (53.0%) 13 (43.3%) 1 (3.3%)
Matched group 30 10 (33.3%) 12 (40.0%) 8 (26.7%)
Treatment group and matched group OCT inspection relatively has significant difference (P<0.05), shows that curative effect obviously is superior to matched group to the treatment group aspect the detachment of retina of optical fundus improving.
The monitoring of 3 safety indexs
It is all normal that 30 routine patient's hearts rate, blood pressure, breathing, pulse, routine blood test, routine urinalysis, stool routine examination, electrocardiogram, liver function, renal function are organized in treatment.
Clinical experimental study shows; The present invention all improves significantly for the cardinal symptom and the optical fundus situation of central serous chorioretinopathy; Can promote the optical fundus seepage to absorb effectively, eliminate the macular area edema, obviously improve the PE layer function; Reduce the macula lutea cicatrization, thereby reach the purpose that therapeutic community's property serous chorioretinopathy becomes.
Model case.
Example 1: Lee, man, 38 years old, workman, first visit in October, 2007.In main suit's right eye blurring of vision companion's 1 week of variable color, rest back nothing alleviates.The patient has long-term history of drinking history, and premorbid work strain stress is bigger, whole body with the time headache is arranged, dizzy, light red tongue, white and thin fur, stringy and rolling pulse.Examination of eyes: vision: right eye: L4.3, the visible macular area edema in optical fundus has circular reflective a wheel, oozes out with tiny; Fluorescence fundus angiography shows: macular area temporo side has 2 fluorescence leakage points that are ink marks appearance.Be diagnosed as central serous chorioretinopathy.Give the present invention treatment, 1 dose of every day, be decocted in water for oral dose.The patient promptly feels the right eye blurring of vision and obviously improves after obeying 5 doses, and look the thing variable color and disappear, ophthalmologic examination: vision: right eye: L4.9, optical fundus macular area edema disappears, and the optical fundus radiography shows that the fluorescence leakage district obviously dwindles.Vision is increased to 5.0 after obeying 10 doses, and the optical fundus radiography shows that the fluorescence leakage district disappears.Follow up a case by regular visits to and do not have recurrence in 1 year.
Example 2: Zhang, woman, 25 years old, certain company clerk, first visit in October, 2008.Whenever the outbreak left eye was looked thing deepening companion blurring of vision 2 years when rest is not good, this outbreak 10 days.Whole body is with fatigue and weak, and pale tongue with white fur is a little less than the stringy pulse.Examination of eyes: vision: left eye: L4.3, the visible macular area edema of fundus photography, canescence is oozed out calmness; Fluorescence fundus angiography shows: the macular area nasal side has 1 spurting fluorescence leakage, and with part blocked fluorescence; OCT shows that the macular area shallow-layer breaks away from, and is diagnosed as central serous chorioretinopathy.Give the present invention treatment, 1 dose of every day, be decocted in water for oral dose.Patient's self-induction left eye is looked the thing deepening and is obviously improved after obeying 15 doses, the more preceding raising of vision, and ophthalmologic examination: vision: left eye: L4.5, optical fundus macular area edema disappears, and the optical fundus radiography shows that the fluorescence leakage district disappears.The 15 doses of backsight thing deepenings of clothes that continue disappear, and vision is increased to L4.9, and OCT shows that macular area does not have obvious disengaging, and sleep improves, and advises the patient to note striking a proper balance between work and rest, and follow up a case by regular visits to and do not have recurrence in 2 years.

Claims (1)

1. the Chinese medicine preparation that becomes of therapeutic community's property serous chorioretinopathy is characterized in that, is made by the crude drug of following weight: Radix Bupleuri 10~15g, Radix Angelicae Sinensis 15~20g, the Radix Paeoniae Alba 10~15g; Poria 15~20g, the Rhizoma Atractylodis Macrocephalae 15~20g, Radix Codonopsis 15~20g, Radix Rehmanniae Preparata 25~30g; Radix Achyranthis Bidentatae 10~15g, Fructus Lycii 10~15g, Semen Cuscutae 12~18g, Fructus Ligustri Lucidi 20~30g; Radix Curcumae 10~15g, Rhizoma Dioscoreae 10~15g, Rhizoma Alismatis 8~15g, Radix Glycyrrhizae 6~10g; Manufacture method: get above-mentioned Chinese medicine, add water 1200-1500kg after the process of preparing Chinese medicine, after the heated and boiled slow fire boiling 40-60 minute, drag for slag and be filtered into decoction.
CN2011101428677A 2011-05-18 2011-05-18 Chinese medicinal preparation for treating central serous retinopathy Expired - Fee Related CN102210841B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101428677A CN102210841B (en) 2011-05-18 2011-05-18 Chinese medicinal preparation for treating central serous retinopathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101428677A CN102210841B (en) 2011-05-18 2011-05-18 Chinese medicinal preparation for treating central serous retinopathy

Publications (2)

Publication Number Publication Date
CN102210841A CN102210841A (en) 2011-10-12
CN102210841B true CN102210841B (en) 2012-07-04

Family

ID=44742525

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101428677A Expired - Fee Related CN102210841B (en) 2011-05-18 2011-05-18 Chinese medicinal preparation for treating central serous retinopathy

Country Status (1)

Country Link
CN (1) CN102210841B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102836316B (en) * 2012-09-19 2014-07-02 张劭茹 Chinese medicine preparation for treating amblyopia
CN103830453A (en) * 2014-03-17 2014-06-04 刘育霞 Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating central serous chorioretinopathy
CN112426462B (en) * 2021-01-05 2022-08-30 河南省科学院 Hydrogel eye patch for adjuvant therapy of central serous chorioretinopathy and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195022A (en) * 2007-12-03 2008-06-11 门连社 Chinese medicine prescription for curing tumor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195022A (en) * 2007-12-03 2008-06-11 门连社 Chinese medicine prescription for curing tumor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
汝亚琴等.中医药治疗糖尿病性视网膜病变概况.《中国中医药信息杂志》.2003,第10卷(第06期), *
王桂红.《中心性浆液性脉络膜视网膜病变的中医治疗近况》.《河北中医》.2001,第23卷(第3期), *

Also Published As

Publication number Publication date
CN102210841A (en) 2011-10-12

Similar Documents

Publication Publication Date Title
CN101810833B (en) Chinese medicinal composition for treating edema and preparation method thereof
CN100493597C (en) Medicine composition for treating neurosis
CN102178815B (en) Traditional Chinese medicine for treating ischemic optic neuropathy
CN102210841B (en) Chinese medicinal preparation for treating central serous retinopathy
CN101953936A (en) Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof
CN101543621B (en) Drug for curing diabetes
CN101703686B (en) Chinese medicinal composition for treating diabetes
CN101700379B (en) Traditional Chinese medicine preparation for treating central serous chorioretinopathy
CN102940785A (en) Traditional Chinese medicine composition for treating vertigo
CN103720857A (en) Traditional Chinese medicinal preparation for treating fundus macular oedema lesion
CN105168590A (en) Traditional Chinese medicine for treating xerophthalmia
CN104587257A (en) Traditional Chinese medicine composition for treating diabetic macular edema
CN101195003B (en) Proprietary Chinese medicine for treating apoplexy and sequela
CN102600424A (en) Chinese herba preparation for treating nephropyelitis and preparation method of Chinese herba preparation
CN102836316B (en) Chinese medicine preparation for treating amblyopia
CN104306546A (en) A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition
CN105381333A (en) Traditional Chinese medicine composition with effects of treating spleen-kidney Yang deficiency
CN107456532A (en) Fragrant thoroughwort hypoglycemic is clear
CN105833065A (en) Traditional Chinese medicine decoction for treating female endocrine dyscrasia and preparation method thereof
CN105833064A (en) Eyesight-improving decoction for treating diabetic retinopathy
CN105853987A (en) Traditional Chinese medicine composition for treating peripheral nerve injury caused by anesthesia and preparing method thereof
CN104758539A (en) Traditional Chinese medicine composition for treating debilitation
CN102125644B (en) Traditional Chinese medicine preparation for treating hypotension of qi-deficiency type
CN103977310A (en) Traditional Chinese medicine preparation for nursing diabetes and preparation method thereof
CN114588243A (en) Formula of two alternately taken traditional Chinese medicines for treating depression and anxiety

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120704

Termination date: 20130518